Autologous peripheral blood stem cells (PBSC), for transplantation following high-dose chemotherapy, are collected using regimens containing cytokines with or without chemotherapy. The added period of neutropenia prior to stem cell transplantation (SCT) in patients receiving chemotherapy mobilization may increase the risk of infections following transplantation. We studied the incidence of culture-positive infections in 107 consecutive patients who were divided into three groups, according to whether they experienced extended neutropenia during chemotherapy for stem cell mobilization as well as post autotransplant. All the patients received antibiotic prophylaxis and hematopoietic growth factors during neutropenia. The total duration of pre-transplant neutropenia differed among the three mobilization schemes (growth factors alone; one cycle; or two cycles of chemotherapy plus growth factor for mobilization) at 0, 6 and 18 days, respectively (median). However the post-autograft time to myeloid engraftment was similar at 10 days (median). The incidence of culture-proven infections in all three groups was similar. Using fluconazole for yeast prophylaxis, 40% patients developed gastrointestinal colonization with yeast, and the majority of speciated isolates were Candida glabrata. Bacteremia developed in 22% and 9% of patients with S. epidermidis and Gram-negative organisms, respectively, while 11% developed C. difficile-associated diarrhea. In conclusion, treatment using none, one or two cycles of mobilizing chemotherapy pretransplant does not influence the overall incidence of infections among autologous SCT recipients. However, although post-transplant neutropenia is brief, infections remain a significant cause of morbidity. Bone Marrow Transplantation (2001) 28, 1129-1134.
High-dose chemotherapy with autologous peripheral blood stem cell (PBSC) or bone marrow (BM) transplantation has become accepted consolidation or salvage therapy for various hematologic malignancies. Rapid hematopoietic reconstitution with the use of mobilized PBSC grafts, as well as the use of hematopoietic growth factors after transplant, has reduced morbidity and mortality by shortening post-transplant neutropenia and its attendant complications. Antibiotic and antifungal prophylaxis as well as transfusion support have also permitted moving much of the autologous PBSC transplant course to an outpatient setting. [1] [2] [3] Stem cells can be mobilized using either cytokines alone or a combination of chemotherapy and cytokines. When PBSC are mobilized using chemotherapy and cytokines, patients sustain an additional period of neutropenia prior to transplantation. This additional period of neutropenia may contribute to an increased risk of infection during PBSC mobilization and possibly during the subsequent autologous stem cell transplantation. In addition, these patients receive prophylactic antifungal and antibiotic therapies during mobilization, which may provide enough drug pressure to alter the colonizing microbial flora and/or drug susceptibility patterns during the early post-transplant period.
We reviewed all episodes of microbiologically documented infections occurring in three patient groups receiving either growth factors alone or receiving one or two cycles of stem cell mobilizing chemotherapy and during the first 30 days following autologous PBSC transplantation. The incidence and consequences of these infections are reported.
Materials and methods

Patients
This retrospective cohort study included consecutive adult patients undergoing autologous PBSC or BM transplantation at the University of Minnesota between March 1996 and April 1998 (Table 1) . Patients with acute myelogenous leukemia (AML) were excluded because of their prolonged neutropenia and infectious complications during the induction and consolidation phases of AML therapy before referral for transplantation. Shown are number (%) of patients with specific characteristics. PBSC = peripheral blood stem cells; BM = bone marrow.
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Pre-transplant chemotherapy and transplantation
One patient group received only G-CSF for mobilization of peripheral blood progenitor cells (group 1). In groups 2 and 3, patients were given the mobilizing chemotherapy (Table 2) . Chemotherapy was given in the hospital over 48-72 h, then patients were observed with daily follow-up in the outpatient setting. PBSC were collected by apheresis and cryopreserved. Patients were re-admitted for administration of the myeloablative regimen. On the day after infusion of the cryopreserved graft (day +1), patients were discharged if they met pre-determined criteria: no fever, no uncontrolled infection, adequate oral or transdermal nausea and pain relief, sufficient oral intake to require no more than 1 liter of i.v. fluid and one platelet transfusion daily. After discharge they were followed in the transplant clinic on a daily basis until neutrophil engraftment (3 days of ANC Ͼ0.5 × 10 3 /l).
Infection prophylaxis and therapy
All patients received antibiotic prophylaxis with oral penicillin-VK 250 mg four times a day and ciprofloxacin 500 mg twice a day for a minimum of 10 days following the administration of mobilizing chemotherapy and after infusion of the autograft until recovery from neutropenia.
Patients also received prophylaxis with trimethoprim/ sulfamethoxazole (160 mg/800 mg) orally twice a day and fluconazole 200 mg once a day. Individuals sero-positive for CMV were given acyclovir 800 mg five times a day for the first 2 months after transplantation. For fever у37.8°C all patients had cultures from blood and other sites as clinically indicated. Patients initially received broad-spectrum intravenous antibiotics (third generation cephalosporin + vancomycin), later individually modified according to microbial culture and sensitivity data. Weekly surveillance cultures from stools were done for patients with diarrhea. If diarrhea developed, stool samples were sent for yeast and bacterial pathogens as well as Clostridium difficile culture and toxin assay. Of note, our laboratory assay detects only C.difficile toxin A, not B.
Following transplantation, weekly surveillance for CMV was carried out in all patients. The shell vial culture method was used until mid-1996, and was replaced with CMV pp65 antigenemia assays thereafter. Rapid fluorescent antigen assay and viral culture was performed on nasopharyngeal swabs or broncho-alveolar lavage (BAL) fluid for respiratory viruses when suspected. BAL was performed in patients with dyspnea, cough or other respiratory symptoms along with an abnormal chest X-ray, with or without fever.
Statistical analysis
Patient data were obtained from the University of Minnesota Bone Marrow Transplant Database, which contains prospectively collected data on all patients undergoing transplant therapy at our center. The peri-transplant time period was reviewed for positive culture results starting from the initiation of mobilizing chemotherapy until day +30 following stem cell transplantation. Neutropenia was defined as an ANC Ͻ0.5 × 10 3 /l. Blood, stool, throat and BAL culture results as well as all pathological data were obtained from the hospital laboratory records and/or medical charts. Culture isolates were recorded as separate infection episodes if isolated Ͼ1 week apart for blood or Ͼ4 weeks apart for stool. Culture-negative febrile episodes were not included in this analysis.
Prior to the collection of data, patients were categorized into three groups based on the number of pre-transplant stem cell mobilizing chemotherapy courses given ( Table 2) . Breast cancer patients (group 1) received only G-CSF to mobilize their stem cells and formed the control group because they received no mobilization chemotherapy and thus had no pre-transplant neutropenia. Patients with Hodgkin's disease (HD) or non-Hodgkin's lymphoma (NHL) (group 2) were mobilized with G-CSF alone at first; this was then followed by one course of chemotherapy plus growth factor mobilization. Chronic myelogenous leukemia (CML) patients were included in group 2 as they were mobilized using a single cycle of chemotherapy. Patients with multiple myeloma (MM) received two cycles of pre-transplant chemotherapy plus G-CSF or granulocyte-macrophage colony-stimulating factor (GM-CSF) (group 3).
The expected number of infectious episodes in each group was calculated from the number of observed episodes in the whole cohort and the number of patients in each group. Using these data, a chi square test of significance was done in order to compare differences observed between the groups.
Results
Patients
Of the 107 patients undergoing autologous SCT from March 1996 to April 1998, the median age was 46 years (range 14 to 63 years) and 46% were male ( Table 1) . The majority of patients belonged to mobilization group 2 and received one myelosuppressive mobilizing cycle. All 107 (100%) patients received their autograft after undergoing disease-specific, high-dose chemotherapy ( Table 2 ). The interval from mobilizing chemotherapy to stem cell transplant was proportional to the number of cycles of mobilizing chemotherapy administered: in group 3 (MM) the median time from first cycle of mobilizing chemotherapy to transplant was 67 days (range 51-387 days) vs 31 days (range 20-93 days) for group 2 (NHL, HD and CML). The cumulative duration of neutropenia during the pre-transplant mobilizing chemotherapy correlated with the regimen used (Table 3) , longest in group 3 (median 18 days), shorter in group 2 (median 6 days), and no pre-transplant neutropenia in the group 1 patients. After stem cell transplanBone Marrow Transplantation tation, all patients had prompt myeloid engraftment. The median time to neutrophil recovery was 10 days (range 2-16 days) with no significant difference between the three groups (Table 3) . During the 30-day follow-up period only one patient died secondary to sepsis and respiratory failure.
Fungal colonization and infections
Forty percent (43/107) of all patients developed diarrhea and/or gastrointestinal (GI) colonization with identifiable strains of yeasts (Table 3 and 4) . Five patients had two to three different yeast species isolated at different times. Twenty-four patients (28 isolates) had GI colonization with Candida glabrata and three with Candida krusei. Other colonizing yeasts were: 10/107 patients with Candida albicans, 9/107 with Saccharomyces cerevesiae and four patients with other yeasts, Candida guillermondii (n = 2), Rhodotorula rubra (n = 1) and C. tropicalis (n = 1). Four patients with pre-transplant GI C. glabrata colonization had a recurrence following transplant. One group 3 patient colonized with intestinal C. glabrata first developed candidemia 8 days after transplant which persisted for over 2 weeks. Two patients with febrile neutropenia and pulmonary infiltrates had C. glabrata and S. cerevesiae cultured from alveolar lavage fluid. However, despite the varying duration of pre-transplant neutropenia and exposure to antibiotics, there was no significant difference in the incidence of GI colonization by yeasts in the three patient groups (P = 0.4) ( Table 3 ). There was no significant difference between the incidence of various yeasts colonizing patients in group 1 vs groups 2 and 3 (C. albicans 17% vs 7%, C. glabrata 17% vs 24%, P = NS).
Bacterial infections
In the interval from mobilizing chemotherapy to the first month following transplantation, 30 patients (28%) developed 36 episodes of bacteremia (Table 3) . Twentythree patients (75% of bacteremic patients) had Gram-positive bacteria isolated from the blood stream (26 episodes); 82% of these were central venous access catheter-associated coagulase-negative Staphylococcus (Table 4) . Following mobilization chemotherapy Gram-positive bacterial isolates occurred in 12 group 2 and 3 patients at a median of 8 days (range 6-35 days). Fourteen patients (13%) developed bacteremia at a median of 7 days (range 1-25 days) following transplantation. Two patients developed recurrent coagulase-negative staphylococcal bacteremia. The rates of bacteremia were similar in all three groups (P = 0.3).
Despite the use of ciprofloxacin for anti-bacterial prophylaxis, nine patients (8%) developed bacteremia with Gramnegative organisms (Table 4 ). This Gram-negative bacteremia occurred at a median of 4 days (range −2 to 23 days) following SCT. Despite ciprofloxacin prophylaxis, seven of these nine isolates were sensitive to ciprofloxacin. Two patients had polymicrobial sepsis. One group 3 patient had Staphylococcus epidermidis plus Acinetobacter 1 week after mobilizing chemotherapy. One group 2 patient had bacteremia with methicillin-resistant Staphylococcus aureus, Pseudomonas stutzeri and Stenotrophomonas maltophilia 7 days following transplant. Seven patients had GI (Table 3) . A similar incidence was observed in all three groups. Five patients developed C. difficile colitis after PBSC mobilizing chemotherapy and seven following transplant at a median time of 2.5 days (−6 to +18 days). One patient with colitis following mobilizing chemotherapy had a recurrence after transplantation. Of 12 patients with C. difficile-associated diarrhea, seven had the organism identified only on stool culture but had no accompanying positive C. difficile toxin assay, although all responded to therapy with metronidazole. Our laboratory assay detects only C. difficile toxin A, not B, which might, in part, explain this finding.
Viral infections
During pre-transplant evaluation 48 patients (46%) were CMV sero-positive (CMV IgG antibody titer Ͼ15 AU/ml). Three of these patients (6%) developed CMV viremia documented by the CMV antigenemia assay. Two patients had onset of viremia at the time of transplant (day −1 and day 0) and were treated with foscarnet to avoid ganciclovirinduced myelosuppression. CMV pneumonitis developed in one of the three patients and was manifest as fever and diffuse infiltrates on chest X-ray. Bronchoscopy on day +12 demonstrated CMV in culture while the CMV antigen assay was low positive (1/50 000 cells) on day +18. One other patient developed respiratory syncytial virus pneumonitis on day +15 following transplant.
Respiratory infections
Twelve of 107 (11%) patients underwent lower respiratory sampling with BAL in the peri-transplant period (two preceding and 10 at a median of 11 days post transplant), to evaluate dyspnea in the presence of infiltrates on chest Xray. Nine of these patients were febrile. Two patients were found to have diffuse alveolar hemorrhage. Two other patients were diagnosed with engraftment syndrome.
Two patients had yeast isolated from their BAL while stool cultures were positive for the same yeast. One was C. glabrata (after mobilizing chemotherapy) and one S. cerevesiae (day 8 following transplant). These isolates from BAL fluid may represent contamination with oral flora, given the concomitant isolation from the GI tract and the absence of fungemia. There was a single case each of CMV pneumonitis and RSV pneumonitis diagnosed by BAL (see viral infections above). Other BAL-isolated micro-organisms included Hemophilus parainfluenzae from two patients, Enterococcus and S. epidermidis from one patient and viridans streptococci from seven. Six patients had multiple organisms grown from their BAL.
No patient with breast cancer (group 1) had organisms isolated from BAL samples in contrast to those in groups 2 (n = 9) and 3 (n = 1) with hematologic malignancies (P = 0.09). One patient developed invasive pulmonary aspergillosis during the second mobilizing chemotherapy for myeloma, requiring prolonged therapy with amphotericin B for nearly 1 year prior to transplant. During the peritransplant period he died of sepsis and RSV pneumonitis on day +19.
Discussion
In this report we describe the incidence of culture-proven infections in patients undergoing autologous PBSC transplantation. The PBSC mobilizing regimen induced substantial differences in the duration of pre-transplant neutropenia, potentially altering patient vulnerability to opportunistic infections. However, this pre-transplant neutropenia did not substantially alter the incidence of infections or colonization with pathogenic microbes. Of some concern was the high incidence of GI colonization with yeasts, with a high proportion of C. glabrata/krusei species, in these patients whose peri-transplant anti-fungal prophylaxis was fluconazole. Colonization with azole-resistant yeasts may predispose these patients to systemic mycoses, although in this series only one fungemia was observed. Nearly 10% of patients developed C. difficile-associated diarrhea, most likely as a complication of antibiotic therapy, both prophylactic and therapeutic. Despite broad-spectrum antibiotic prophylaxis in the neutropenic phase, 28% patients developed bacteremias, mostly with coagulasenegative staphylococci.
We had anticipated an incremental risk of infectious complications in patients who experienced either one or two episodes of neutropenia prior to transplantation. However, this was not the case. The low observed incidence of infection might be attributable to the prophylactic antimicrobials administered during both mobilization and in the post-transplant period. In addition, the use of G-CSF (or GM-CSF) for stem cell mobilization and hastening hematopoeitic recovery post transplant may have contributed to the low incidence of infections. G-CSF administered following transplant can reduce the time to engraftment and the risk of post-transplant infections. 4 Also, both GM-CSF and G-CSF can enhance neutrophil function in a variety of transplant-and non-transplant-related settings. 5, 6 Previous reports describe up to 12% of transplant patients developing invasive infections with Candida species after SCT, with substantial morbidity and mortality. 7 The duration of neutropenia is well-recognized as a major risk factor for the development of candidiasis. Fluconazole has demonstrated efficacy in reducing the incidence of both colonization and infection with Candida species in SCT and leukemia patients.
8,9 C. krusei and C. glabrata are most
Bone Marrow Transplantation often resistant to the azole antifungals. Patients with GI colonization with these organisms may suffer added risks for developing bacteremia with enteric bacteria, possibly as a result of tissue damage augmented by the mucosal yeast adherence. As a consequence of prophylactic antibiotic therapy, the incidence of C. difficile enterocolitis was substantial with nearly 10% of patients affected. A recent report 10 describing 80 patients undergoing autologous PBSC transplantation found 61 (76.3%) to have developed diarrhea. C. difficile accounted for only 5% of diarrhea. However, in this series 41% of patients with diarrhea received empiric oral metronidazole or vancomycin while awaiting C. difficile diagnostic testing. Barton et al 11 described a 10% incidence of C. difficile colitis in 127 patients undergoing highdose therapy and SCT for breast cancer. Bilgrami et al 12 described 14/200 (7%) patients positive for C. difficile toxin in a retrospective review of patients undergoing autologous SCT. A randomized trial comparing ciprofloxacin with trimethoprim-sulfamethoxazole for infection prophylaxis in BMT patients observed a higher incidence of C. difficile toxin positive enterocolitis: 10 episodes in 71 patients receiving TMP-SMX (14%) vs none in patients receiving ciprofloxacin. 13 An earlier study had found a 5% incidence of C. difficile in 126 patients with diarrhea post transplant, with most episodes having no pathogens identified.
14 These reports and the low enterocolitis incidence in the current trial suggest that therapy for C. difficile should be instituted only for patients with documented infections as long as C. difficile culture and toxin studies are promptly performed in patients with diarrhea. The extended neutropenia and accompanying lengthy antibiotic prophylaxis in groups 2 and 3 did not alter the incidence of enteric superinfection with C. difficile.
We observed a relatively high incidence of central venous catheter-associated bacteremia secondary to coagulase-negative Staphylococcus as well as a modest number of Gram-negative isolates. Similar results have been reported recently. In a retrospective review of 126 patients undergoing autotransplantation receiving prophylaxis with ciprofloxacin, itraconazole and acyclovir, Salazar et al 15 found Gram-positive bacteria responsible for 75% of bacteremias, one-third of which were caused by Staphylococcus epidermidis. Kolbe et al 16 found a similar incidence of neutropenia-associated complications with a 39% incidence of bacteremia among 66 patients. Gram-positive cocci were the predominant pathogens. Offidani et al 17 reported the incidence of infective complications in 150 patients undergoing SCT and found a 13% Gram-positive and a 10% incidence of Gram-negative bacteremia, despite prophylaxis with quinolones and fluconazole. Barton et al 11 reported a somewhat similar incidence of bacteremia (13%) in 127 breast cancer patients undergoing transplantation, with minimal antibiotic prophylaxis using trimethoprimsulfamethoxazole in only 6% of patients. In the current series, the greater, although modest duration of neutropenia in groups 2 and 3 was not complicated by more frequent bacteremia with either Gram-positive or Gram-negative organisms.
We observed a very low incidence of CMV antigenemia and disease and this occurred exclusively in sero-positive patients. This is consistent with earlier reports. [18] [19] [20] In conclusion, this retrospective review showed no increase in infection risk following either one or two cycles of mobilizing chemotherapy prior to SCT. The extra weeks of neutropenia also did not alter the incidence of infection following SCT. Careful prophylaxis, surveillance and attentive supportive care can limit the infectious hazards even in patients undergoing up to three sequential episodes of severe neutropenia.
